Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Phase 2

Study Evaluating Near-infrared Imaging Coupled With Indocyanine Green for Intraoperative Control of Resection Margins in ENT Surgery

NCT04842162 · tracked via the Priya Life Science France tracker
Phase
Phase 2
Started
2020-12-15
Last updated
2025-11-26

Condition(s) studied

Head and Neck Cancer

Investigational drug(s) / intervention(s)

indocyanine green →

indocyanine green: indocyanine green (INFRACYANINE© 25mg/10mL).

Study summary

Assess the sensitivity of real-time near-infrared fluorescence imaging to detect microscopic residual disease in the operating room after a complete macroscopic surgical resection of head and neck cancers

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Male or female 18 years of age or older * ECOG performance status 0-2 * Histological confirmation of squamous cell carcinoma * Locating the primary tumour in the oral cavity or oropharynx * Disease operable for complete resection * Serum or urinary pregnancy test (as per centre practices) negative within 14 days prior to systemic indocyanin green injection (pre-operative visit), for women of childbearing age * Patient information and signed free and informed consent * Patient affiliated with a social security scheme or beneficiary of a similar scheme. * The patient must understand, sign and date the consent form prior to any protocol-specific procedures. The patient must be able and willing to comply with the study visits and procedures described in the protocol Exclusion Criteria: * Severe medical co-morbidities or contraindications to surgery * Primary tumour not operable * History of head and neck cancer in the past 5 years * History of radiation for head and neck cancer * Metastatic cancer * Tumours with necrosis ranges in pre-operative imaging * History of invasive cancer unless there has been no recurrence for more than 5 years with an exception for non-melanoma skin cancers. * Pregnant or nursing woman * Allergy or hypersensitivity to the product being administered (its active substance or other ingredients), iodized products or crustaceans. * Hyperthyroidism, thyroid adenoma, unifocal, multifocal or multinodular goiter of autoimmune origin. * Documented coronary artery disease * Advanced renal failure (creatinine \> 1.5mg/dL). * Within 2 weeks prior to inclusion, concomitant medication that reduces or increases extinction of GI (i.e. anticonvulsants, haloperidol and Heparin). * Patient under guardianship or curatorship or deprived of liberty by judicial or administrative decision or patient unable to give consent. * Patients unable to undergo medical follow-up of the trial

Primary outcome measure(s)

  • Sensitivity of Near Infrared Fluorescence Imaging — at surgery
    Sensitivity of real-time near-infrared fluorescence imaging to detect microscopic residual disease in the operating room after complete macroscopic surgical resection. For the calculation of the sensitivity, for each operating room we consider the first section and the last section in which the pathological analysis confirms the presence of microscopic residual disease. Patients for whom near-infrared fluorescence imaging detects disease are classified as true positives (TP). Sensitivity is defined as the number of TP divided by the total number of patients N.

Trial sites (2)

FacilityCityRegionStatus
Institut Jules Bordet Anderlecht Belgium Recruiting
Gustave Roussy Villejuif Val De Marne Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04842162 on ClinicalTrials.gov ↗ ← All trials in France